Production of 4′-epidaunorubicin by metabolic engineering of Streptomyces coeruleorubidus strain SIPI-1482

Abstract

Streptomyces coeruleorubidus strain SIPI-1482 is an important industrial microbial strain which produces daunorubicin, the precursor for semi-synthesis of first-line anti-tumor antibiotics doxorubicin and epirubicin. dnmV, the C4 ketoreductase gene in the biosynthetic pathway of TDP-l-daunosamine was successfully disrupted by homologue recombination. The SIPI-1482 dnmV-blocked mutant lost the ability to produce daunorubicin and aggregate the intermediate e-rhodomycinone. By introducing dnmV, the daunorubicin biosynthetic pathway in S. coeruleorubidus was reconstituted. Further more, aveBIV from S. avermitilis, as well as oleU from S. antibiotics, and novS from S. niveus were introduced into the dnmV-blocked mutant. The SIPI-1482 dnmV::aveBIV mutant could produce 4′-epidaunorubicin instead of daunorubicin, but dnmV::oleU and dnmV::novS mutant could not. Our study showed that the genetically engineered strain had a different fermentation condition and extraction protocol compared with the wild type daunorubicin producer. These results suggest that metabolic engineering is a powerful tool to produce novel hybrid antibiotics and a good alternative to chemical synthesis.